If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.75
Bid: 34.50
Ask: 35.00
Change: 0.00 (0.00%)
Spread: 0.50 (1.449%)
Open: 34.75
High: 34.75
Low: 34.75
Prev. Close: 34.75
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

5 Nov 2008 07:00

RNS Number : 4604H
China Real Estate Opportunities Ltd
05 November 2008
 

5 November 2008

China Real Estate Opportunities Limited

Business Update

China Real Estate Opportunities ("CREO" or the "Company"), an AIM listed property company with an established investment and development property portfolio in China, today provides an update on the Company's trading since 1 July 2008.

 

 Investment Highlights:

Strong Income Producing Portfolio Continues to Outperform

CREO's income producing assets, which represent 75% of the Company's total portfolio, have continued to perform strongly in the third quarter. Three year rollover on leases, which is standard practice in China, has enabled the Company to continue to drive income growth in the short to medium term.

Office: CREO achieved between 10% to 50% rental income growth from lease renewals and new leases since 1 July 2008.

Occupancy rates in the investment assets remain strong:

Central Plaza: 92% 

City Center: 95% 

Treasury Building: 97% 

Retail: CREO has completed 21 lease renewals and new leases since 1 July 2008, and has achieved up to 40% increase in rents on individual transactions and an average of over 16% growth from letting transactions in the period

Development Highlights: 

CREO's development programme continued to make progress throughout the period

Beijing Logistics Park: construction is due to commence in November 2008. Completion of this development project is expected in 2009, and the Company has already received strong leasing enquiries.

Central Plaza: office tower refurbishment work is on schedule for completion before the end of 2008 while the remainder of the refurbishment programme is on track for completion in 2009.

City Center: short-term refurbishment work will be completed in Q1 2009. 

City Center Extension (formerly referred to as CC3): the design and planning process is proceeding as outlined earlier this year.

City Center Development (formerly referred to as CC5): on track to commence in the current quarter. 

Financing

The maturity profile of CREO loans secured against its investment properties remains unchanged with all existing loans locked in until Q3 2010

In addition, CREO has recently secured a new development loan facility from DBS Bank in relation to the construction of its Beijing Logistics Park development.

The Chinese Market: Robust Office & Retail Markets

China's annualised GDP growth in the quarter to September 30 was a strong 9.0%(1) and 9.9% for the year to date(1), highlighting considerable continued momentum and although the prospects for the China economy are not immune to the deteriorating external environment, this growth trend represents a strong foundation for China to weather the current economic upheaval.

China's retail sales increased by 22% in the last nine months(1), underpinning continued strong demand for retail space. In addition, the Shanghai retail rental market continued to enjoy a buoyant performance with growth of 5.7% quarter on quarter, whilst vacancy rates were down by 0.4% in the quarter as demand, in particular from international retail, continues(2).

Shanghai prime office rental performance was stable overall in Q3, following the impact of considerable additional supply in recent months which led to an increase in market vacancy rates(2) during the quarter. Within this context, the CREO portfolio has delivered a strong performance, evidenced by maintained strong occupancy and rental growth in the last quarter.

"During this period of unprecedented market volatility and uncertainty seen in global equity and debt markets, the focus of CREO Directors has been to continue to manage its assets intensively and deliver growth. As a result, the business has continued to perform strongly in the period. CREO's income producing portfolio continues to see significant uplifts in rental income arising from rental reviews and new lettings, reflecting a resilient rental market."

"Activity in the CREO development portfolio continues at pace as construction of the Beijing Logistics Park is about to commence and the planning process for the City Center Extension development is underway. The Company is positioned to continue to perform well in the short and medium term.", commented Ray Horney, CREO Chairman.

(1) PRC National Bureau of Statistics

(2) CBRE China, Q3 2008 MarketView

-----------ENDS---------

  

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0)1273 775225

Sarah Moriarty, Investor Relations 

Tel: +353 1 6189455

Davy

Des Carville

Tel: +353 1 679 6363

Bankside Consultants

Simon Rothschild, Oliver Winters

Tel: + 44 (0)207 367 8888

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFSAEELSASEFF
Date   Source Headline
7th May 20247:00 amRNSCreo Medical receives King’s Award for Enterprise
25th Apr 20247:00 amRNSNotice of Results
24th Apr 20247:00 amRNSNHS Speedboat data demonstrates savings
20th Mar 20244:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSWelsh Labour Leader visits Creo’s facilities
13th Mar 20243:05 pmRNSHolding(s) in Company
11th Mar 20242:00 pmRNSLTIP Awards
6th Mar 20244:35 pmRNSHolding(s) in Company
1st Mar 20247:00 amRNSMicrowave Lung Ablation Update
7th Feb 20249:12 amRNSTrading Update - Replacement
7th Feb 20247:00 amRNSTrading Update
5th Feb 20247:00 amRNSStrategic Collaboration with Khalifa University
31st Jan 20247:00 amRNSSpeedboat® UltraSlim roll-out reaches Asia Pacific
22nd Jan 20247:00 amRNSAward of Shares under Share Incentive Plan
10th Jan 20247:00 amRNSFirst use of Speedboat® UltraSlim in Latin America
15th Dec 20237:00 amRNSFirst use of Speedboat® UltraSlim in the USA
13th Dec 20237:00 amRNSFirst European Speedboat® UltraSlim procedure
7th Nov 20237:00 amRNSCapital Markets Day
1st Nov 20237:00 amRNSSpeedboat® UltraSlim: US FDA Clearance
25th Oct 20237:00 amRNSSB UltraSlim: EU launch accelerated by 18 months
16th Oct 202310:16 amRNSChange of Nominated Adviser and Joint Broker
12th Oct 20237:00 amRNSInvestor Presentation
12th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSNotice of Results
16th Aug 20237:00 amRNSRoyal Oldham SSD service update
3rd Aug 20237:00 amRNSHalf Year Trading Update
28th Jul 20237:00 amRNSTotal Voting Rights
24th Jul 202310:40 amRNSAward of Shares under Share Incentive Plan
6th Jul 202311:33 amRNSIssue of Equity and TVR
27th Jun 20231:15 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement & Directorate Succession Planning
26th Jun 20237:00 amRNSFirst upper GI Speedboat procedure in Europe
22nd Jun 20237:00 amRNSAppointment of Marco Scarci
19th Jun 20237:00 amRNSSpeedboat Inject upper GI clearance in Europe
1st Jun 20237:00 amRNSSpeedboat™ Inject selected by NICE for assessment
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFirst in-human milestone for MicroBlate™ Flex
17th May 20237:00 amRNSRoyal Oldham Hospital Agreement
15th May 20237:00 amRNSAttendance at Digestive Disease Week
26th Apr 20237:00 amRNSFinal Results
14th Apr 20237:00 amRNSAlbyn Medical earn out update
31st Mar 202310:45 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSMicroBlate™ Flex clinical study
13th Mar 20236:13 pmRNSDirector/PDMR and PCA Share Dealings
13th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 202310:25 amRNSResult of GM
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.